<DOC>
	<DOCNO>NCT02164864</DOCNO>
	<brief_summary>The main objective study compare Dual Antithrombotic Therapy ( DAT ) regimen 110mg dabigatran etexilate b.i.d . plus clopidogrel ticagrelor ( 110mg DE DAT ) 150mg dabigatran etexilate b.i.d . plus clopidogrel ticagrelor ( 150mg DE-DAT ) Triple Antithrombotic Therapy ( TAT ) combination warfarin plus clopidogrel ticagrelor plus ASA &lt; = 100mg daily ( warfarin-TAT ) patient Atrial Fibrillation undergo PCI stenting ( elective due Acute Coronary Syndrome ) . The study aim show non-inferiority dose DE-DAT compare Warfarin-TAT term safety . Safety determine compare rate bleed event , assess use modify International Society Thrombosis Haemostasis classification Major Bleeding Clinically Relevant Non Major Bleeding Events .</brief_summary>
	<brief_title>Evaluation Dual Therapy With Dabigatran v . Triple Therapy With Warfarin Patients With AF That Undergo PCI With Stenting ( REDUAL-PCI )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Male female patient age &gt; =18 year Patients Non Valvular Atrial Fibrillation Patient presenting : An ACS ( STEMI , NonSTEMI [ NSTEMI ] unstable angina [ UA ] ) successfully treat PCI stenting ( either Bare Metal Stent Drug Eluting Stent ) Or Stable Coronary Artery Disease least one lesion eligible PCI successfully treat elective PCI stenting ( either BMS DES ) The patient must able give informed consent accordance International Conference Harmonisation Good Clinical Practice guideline local legislation and/or regulation . Exclusion criterion : Patients mechanical biological heart valve prosthesis Cardiogenic shock current hospitalisation Stroke within 1 month prior screen visit Patients major surgery within month prior screen Gastrointestinal haemorrhage within one month prior screening , unless , opinion Investigator , cause permanently eliminate Major bleed episode include lifethreatening bleed episode one month prior screen visit Anaemia ( haemoglobin &lt; 10g/dL ) thrombocytopenia include heparininduced thrombocytopenia ( platelet count &lt; 100 x 109/L ) screening Severe renal impairment ( estimate CrCl calculate CockcroftGault equation ) &lt; 30mL/min screen Active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>